{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 20 of 51', 'Study ID RCB: 2020-A00652-37', '8', 'Research Question and Objectives', '8.1 Primary Objective', 'The primary endpoint will be the evaluation at week 12/16 of the sensitivity and the specificity,', 'compared to the DLQI as a standard, of the PSO-TARGET QoL component grid to assess the', 'level of satisfaction of patient achieving the therapeutic goal, identified by himself.', 'The therapeutic objective will be considered as achieved if the patient gives the responses', '\"Satisfied\" or \"Very Satisfied\" on the Likert scale. The response will then be compared to the', 'DLQI score at 12/16 weeks.', '8.2 Secondary Objectives', '- Evaluate the percentage of patients who consider their target objective as being achieved', 'after 12/16 weeks of treatment as defined by a \"satisfied or very satisfied\" response.', '-', 'Level of concordance between the satisfaction level in regard to the therapeutic', 'objective set by the PSO-TARGET QoL Component grid and the DLQI at the 2nd follow-up', 'visit (52 4 weeks.).', '-', 'Evaluate the level of agreement between the dimensions reported by the patient and by', 'the treating physician at baseline.', '-', 'Follow the degree of completeness of the main treatment goal identified at baseline after', '52 weeks.', '-', 'Follow evolution of the PASI score (at 12/16 and 52 weeks).', '-', 'Level of accordance between PASI 90/100 and the satisfaction level in regard to the', 'therapeutic objective set by the PSO-TARGET QoL Component grid.', '-', 'Follow evolution of the DLQI score (at 12/16 and 52 weeks).', '-', 'Evaluate the rate of patients who change their therapeutic objective after 12/16 weeks', 'of treatment.', '9', 'Research Method', '9.1 Study Design', '9.1.1', 'Eligibility criteria', 'The inclusion criteria are the following:', 'Age > 18 years', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 21 of 51', 'Study ID RCB: 2020-A00652-37', 'Patient for whom the dermatologist decided to initiate a treatment by Kyntheum', 'according to SmPC.', 'Patient who signed an informed consent.', 'The following non-inclusion criteria will be applied:', 'Vulnerable subjects according to the law;', 'pregnant, parturient or breast feeding women;', 'deprived of their freedom by administrative, medical or legal decision or', 'who is under trusteeship/guardianship;', 'legally protected, or unable to express their consent to participate;', 'With no affiliation to a social security system;', 'Psychologically/linguistically unable to express their consent to participate;', 'With an hypersensitivity to at least one of the excipients of Kyntheum', 'Participating at the same time in another clinical trial.', '9.1.2 PSO-TARGET Quality of Life Component grid.', 'As a first step to construct the component grid, a retrospective survey based on the', \"recollection and experience from 3 clinical dermatologists (2 French and 1 Belgian) of patient's\", 'expectations, has been conducted. The results of the survey have been used to generate a grid', 'containing 12 therapeutic goals equally distributed into the 4 major psychometric components', 'classically used in quality of life studies in patients suffering from chronic diseases (Chassany,', '2003; Forestier et al., 2019). These four dimensions (cf table 1) are the following:', '- Physical: autonomy, physical capabilities, ability to perform daily activities;', '- Subjective: linked to experienced emotion, anxiety, well-being;', '-', 'Relational/social: with family, friendship or professional environment, engaging', 'personal relationships, involvement in social or leisure activities;', '- Therapeutic: linked to treatment, for ex. treatment-/care-related discomfort.', 'The investigators participating to the study will agree to implement this table as part of their', 'standard of care along with the DLQI questionnaire.', 'Table 1: Quality of Life (QoL) component grid', 'Physical', 'Subjective', 'Relational/social', 'Therapeutic', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}